Journal of Autism and Developmental Disorders

, Volume 33, Issue 1, pp 77–85

Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study

  • Andrés Martin
  • Kathleen Koenig
  • George M. Anderson
  • Lawrence Scahill
Article

DOI: 10.1023/A:1022234605695

Cite this article as:
Martin, A., Koenig, K., Anderson, G.M. et al. J Autism Dev Disord (2003) 33: 77. doi:10.1023/A:1022234605695

Abstract

The objective of this study was to assess the efficacy and tolerability of low-dose fluvoxamine (1.5 mg/kg/day) in youngsters with pervasive developmental disorders (PDDs). This was a prospective, open-label trial that included 18 subjects with a mean age of 11.3 ± 3.6 years. Fourteen children (78%) completed the 10-week study. Premature discontinuation due to behavioral activation occurred in three participants. Although there was no response for the group as a whole, eight subjects (including all four females) were considered at least partial responders in intent-to-treat analyses. Neither pubertal status nor serotonin levels predicted clinical response. Fluvoxamine can be beneficial in the treatment of select children and adolescents with PDDs. Gender differences in selective serotonin reuptake inhibitor (SSRI) response warrant further investigation.

Fluvoxamine PDD Asperger autism serotonin 

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • Andrés Martin
    • 1
    • 2
    • 3
  • Kathleen Koenig
    • 1
  • George M. Anderson
    • 1
    • 4
  • Lawrence Scahill
    • 1
    • 5
  1. 1.Child Study CenterYale UniversityNew Haven
  2. 2.Children's Psychiatric Inpatient ServiceYale-New Haven HospitalNew Haven
  3. 3.Child Study CenterYale University School of MedicineNew Haven
  4. 4.Department of Laboratory Medicine, School of MedicineYale UniversityNew Haven
  5. 5.School of NursingYale UniversityNew Haven

Personalised recommendations